Atlas Trials

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS

Clinical trial NCT03505021 · COMPLETED

Trial details

NCT number
NCT03505021
Sponsor
Orion Corporation, Orion Pharma
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Amyotrophic Lateral Sclerosis
Start date
2018-06-21
Primary completion
2020-07-23
Enrollment
496

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.